Adverum Biotechnologies Reports Second Quarter 2024 Financial Results and Provides Program and Corporate Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- S&P, Dow edge higher on Mideast deal hopes; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Oppenheimer Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
August 13, 2024 6:54 AM EDTOppenheimer analyst Francois Brisebois reiterated an Outperform rating and $28.00 price target on Adverum Biotechnologies (NASDAQ: ADVM).
The analyst comments "ADVM reported its 2Q24 with EPS coming in at ($0.89), beating both our estimated ($1.25) and Street's ($1.47)E. As ADVM continues to focus on the... More
H.C. Wainwright Reiterates Buy Rating on Adverum Biotechnologies (ADVM)
August 13, 2024 6:11 AM EDTH.C. Wainwright analyst Matt Caufield reiterated a Buy rating and $30.00 price target on Adverum Biotechnologies (NASDAQ: ADVM)
The analyst comments "Anticipating 9-month support for injection benefit and safety. We believe the most important near-term catalyst, for wet AMD single-injection intravitreal (IVT) gene therapy candidate Ixo-vec, is the anticipated 4Q24 landmark 9-month analysis from the ongoing Phase 2 LUNA trial of Ixo-vec in wet AMD. While appreciating the full 52-week... More
